It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Infection or vaccination leads to the development of germinal centers (GC) where B cells evolve high affinity antigen receptors, eventually producing antibody-forming plasma cells or memory B cells. Here we follow the migratory pathways of B cells emerging from germinal centers (BEM) and find that many BEM cells migrate into the lymph node subcapsular sinus (SCS) guided by sphingosine-1-phosphate (S1P). From the SCS, BEM cells may exit the lymph node to enter distant tissues, while some BEM cells interact with and take up antigen from SCS macrophages, followed by CCL21-guided return towards the GC. Disruption of local CCL21 gradients inhibits the recycling of BEM cells and results in less efficient adaption to antigenic variation. Our findings thus suggest that the recycling of antigen variant-specific BEM cells and transport of antigen back to GC may support affinity maturation to antigenic drift.
Activated B cell enter germinal centers (GC) to become plasma cells and memory B cells. Here the authors show that some memory B cells recycle to GC via CCL-21 mediated chemotaxis to deliver antigens from the lymph node subcapsular sinus (SCS) to potentially contribute to affinity maturation and antigenic drift.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details











1 University of Birmingham, Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, Birmingham, UK (GRID:grid.6572.6) (ISNI:0000 0004 1936 7486)
2 Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); Deutsches Rheuma-Forschungszentrum (DRFZ), a Leibniz Institute, Berlin, Germany (GRID:grid.418217.9) (ISNI:0000 0000 9323 8675)
3 University of Cambridge Molecular Immunity Unit, MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, UK (GRID:grid.42475.30) (ISNI:0000 0004 0605 769X)
4 Universities of Birmingham and Nottingham, Centre of Membrane Proteins and Receptors (COMPARE), Birmingham, UK (GRID:grid.6572.6) (ISNI:0000 0004 1936 7486); University of Birmingham, Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, Birmingham, UK (GRID:grid.6572.6) (ISNI:0000 0004 1936 7486)
5 The Francis Crick Institute, London, UK (GRID:grid.451388.3) (ISNI:0000 0004 1795 1830)
6 University of Birmingham, Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, Birmingham, UK (GRID:grid.6572.6) (ISNI:0000 0004 1936 7486); The Francis Crick Institute, London, UK (GRID:grid.451388.3) (ISNI:0000 0004 1795 1830)
7 University of Birmingham, Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, Birmingham, UK (GRID:grid.6572.6) (ISNI:0000 0004 1936 7486); The National Polytechnic Institute, Cinvestav-IPN, Av. IPN 2508, San Pedro Zacatenco, Gustavo A. Madero, Department of Cell Biology, Center for Research and Advanced Studies, Mexico City, Mexico (GRID:grid.512574.0)
8 Thymus Biology Section, Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
9 University of Tokushima, Division of Experimental Immunology, Institute of Advanced Medical Sciences, Tokushima, Japan (GRID:grid.267335.6) (ISNI:0000 0001 1092 3579)
10 The National Polytechnic Institute, Cinvestav-IPN, Av. IPN 2508, San Pedro Zacatenco, Gustavo A. Madero, Department of Cell Biology, Center for Research and Advanced Studies, Mexico City, Mexico (GRID:grid.512574.0)
11 Osaka University, Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971); Laboratory of Lymphocyte Differentiation, RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, Japan (GRID:grid.509459.4) (ISNI:0000 0004 0472 0267)
12 The Francis Crick Institute, London, UK (GRID:grid.451388.3) (ISNI:0000 0004 1795 1830); Imperial College, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
13 Queen Mary University London, Centre for Microvascular Research, The William Harvey Research Institute, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133); Queen Mary University London, Centre for Inflammation and Therapeutic Innovation, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133); Ludwig-Maximilians University, Institute for Cardiovascular Prevention, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)